Literature DB >> 23044776

Gastrointestinal cancer: A promising horizon for cediranib?

M Teresa Villanueva.   

Abstract

Entities:  

Year:  2012        PMID： 23044776     DOI： 10.1038/nrclinonc.2012.172

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  2 in total

1.  Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).

Authors:  Paulo M Hoff; Andreas Hochhaus; Bernhard C Pestalozzi; Niall C Tebbutt; Jin Li; Tae Won Kim; Krassimir D Koynov; Galina Kurteva; Tamás Pintér; Ying Cheng; Brigitte van Eyll; Laura Pike; Anitra Fielding; Jane D Robertson; Mark P Saunders
Journal:  J Clin Oncol       Date:  2012-09-10       Impact factor: 44.544

2.  Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).

Authors:  Hans-Joachim Schmoll; David Cunningham; Alberto Sobrero; Christos S Karapetis; Philippe Rougier; Sheryl L Koski; Ilona Kocakova; Igor Bondarenko; György Bodoky; Paul Mainwaring; Ramon Salazar; Peter Barker; Bijoyesh Mookerjee; Jane Robertson; Eric Van Cutsem
Journal:  J Clin Oncol       Date:  2012-09-10       Impact factor: 44.544
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.